AstraZeneca rolls out Forxiga combo drug in U.K.; Roche vs. Apotex patent fight goes forward; Sanofi's Aubagio wins coverage in Scotland;

@FiercePharma: Yesterday's top-read news: Gilead's Sovaldi sales through the roof already, analyst predicts at least $8B this year. Story | Follow @FiercePharma

@TracyStaton: Every Dog Has Its Data: The quantified self for pets, via The New York Times. Article (sub. req.) | Follow @TracyStaton

@EricPFierce: Pfizer's Effexor XR one of a host of recalls lately that include products from Mylan, Baxter and Gilead. More | Follow @EricPFierce

@CarlyHFierce: As promised: BTG recoils at rattlesnake roundup 'gassing.' Item | Follow @CarlyHFierce

> AstraZeneca ($AZN) launched its combination diabetes drugs Xigduo in the U.K. and won a recommendation for health service use of its related drug, Forxiga, in Scotland. Report

> Roche's ($RHHBY) Genentech unit can pursue its patent claims against the generics maker Apotex, a federal judge ruled, allowing a patent fight over the antiviral Valcyte to proceed. Report

> Sanofi ($SNY) won a place on Scotland's National Health Service formulary for its multiple sclerosis pill Aubagio. Report

> A U.S. judge kicked a Plavix marketing case back to West Virginia court, thwarting Bristol-Myers Squibb ($BMY) and Sanofi's ($SNY) attempt to move it to federal court. Report

> U.S. cancer doctors worry that they won't be able to handle a surge in cancer cases at proposed Medicare reimbursement rates, at a time when costs of treatment, including drugs, are rising. Report

> Australia has scrapped its Pharmaceutical Benefits Pricing Authority, which makes pricing recommendations to government officials, as of April 1. Report

Medical Device News

@FierceMedDev: Lombard Medical in the U.K. detailed plans for a proposed $80M IPO driven by its aortic repair device. S-1 form | Follow @FierceMedDev

@MarkHFierce: Exosome Diagnostics raised $27M to bring its prostate cancer urine test to market. More | Follow @MarkHFierce

@MichaelGFierce: Nanoparticles breach blood-brain barrier as possible Alzheimer's treatment. Item from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Industry report shows bleak 2013 for med tech industry. Story | Follow @EmilyWFierce

@GalenMoore: Spanish researchers find a protein adults need for brain plasticity could delay the effects of Alzheimer's disease. Abstract | Follow @GalenMoore

> Roche and Bayer expand their companion Dx partnership into multiple projects. Article

> TriVascular envisions a $100M IPO to propel AAA stent graft rollout. News

Biotech News

@FierceBiotech: Kythera buys back Bayer's stake in PhIII chin-fat therapy in $84M deal. News | Follow @FierceBiotech

@JohnCFierce: Commentary--The dying child vs. the biotech: Everybody loses. Editor's Corner | Follow @JohnCFierce

@DamianFierce: Yesteryear's megamergers are, in part, driving Big Pharma's external R&D push, says John LaMattina. Forbes piece | Follow @DamianFierce

@EmilyMFierce: Scientists from Notre Dame ID new class of antibiotics to combat MRSA. Story | Follow @EmilyMFierce

> Lumena banks $45M and hits the gas on two liver treatments. More

> Novartis's new Basel campus reflects Vasella's (now out-of-fashion) style. Article

Biotech Research News

> University of Notre Dame team IDs new class of antibiotics. Article

> Stem cell therapy improves Parkinson's symptoms in monkeys. Story

> NIH faces flat funds in president's 2015 budget proposal. News

> Seattle BioMed receives $10M NIAID grant to lead AIDS vaccine effort. News

> Antipsychotic drugs may have another use: Treating deadly brain tumors. Story

> OHSU opens new stem cell research center. Brief

Pharma Manufacturing News

> BMS joins Merck with plans to whack plants in Ireland. News

> Global rise in pain drug use puts the hurt on Tasmania's poppy production. Story

> Source: Ranbaxy shops for Nexium API to salvage lucrative launch. Article

> Ranbaxy recalls generic Lipitor after druggist finds 20-mg dose in 10-mg bottle. News

> Pfizer recalls bottles of antidepressant that might have a heart drug mixed in. Story

> Pfizer is expanding its plant in Indonesia--again. Brief

And Finally... The state of Colorado brought in about $2 million in extra tax revenue during the first month of recreational marijuana sales there. Report

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.